AR070530A1 - COMPRESSED ORAL DISINTEGRATION - Google Patents

COMPRESSED ORAL DISINTEGRATION

Info

Publication number
AR070530A1
AR070530A1 ARP090100682A ARP090100682A AR070530A1 AR 070530 A1 AR070530 A1 AR 070530A1 AR P090100682 A ARP090100682 A AR P090100682A AR P090100682 A ARP090100682 A AR P090100682A AR 070530 A1 AR070530 A1 AR 070530A1
Authority
AR
Argentina
Prior art keywords
disintegrating tablet
classes
oral disintegrating
group
tablet according
Prior art date
Application number
ARP090100682A
Other languages
Spanish (es)
Inventor
Naoki Kamada
Masafumi Toda
Hidekazu Okazaki
Tadashi Fukami
Haruka Koizumi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR070530A1 publication Critical patent/AR070530A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un comprimido desintegrante oral que comprende cilostazol, manitol, sacárido distinto de manitol, sustancia inorgánica, y agente desintegrante, así como excipiente orgánico y deslizante, que es posible tomar con manipulacion sencilla por muchos pacientes a los cuales se aplican los comprimidos de cilostazol, especialmente pacientes de edad avanzada y pacientes que sufren de disfagia. Reivindicacion 4: El comprimido desintegrante oral de acuerdo con la reivindicacion 3, caracterizado porque el deslizante es una o más clases de deslizantes seleccionadas del grupo que consiste de dioxido de silicio hidratado, ácido silícico anhidro liviano, y ácido silícico anhidro pesado. Reivindicacion 7: El comprimido desintegrante oral de acuerdo con la reivindicacion 6, caracterizado porque el excipiente orgánico es una o más clases de excipientes seleccionadas del grupo que consiste de almidones y celulosa. Reivindicacion 13: El comprimido desintegrante oral de acuerdo con cualquiera de las reivindicaciones 1 a 12 caracterizado porque opcionalmente también puede comprender una o más clases de aditivos seleccionado del grupo que consiste de lubricantes, edulcorantes, sustancias saborizantes, aromatizantes, aglutinantes y colorantes.The present invention relates to an oral disintegrating tablet comprising cilostazol, mannitol, saccharide other than mannitol, inorganic substance, and disintegrating agent, as well as organic and sliding excipient, which can be taken with simple manipulation by many patients to whom they are applied. Cilostazol tablets, especially elderly patients and patients suffering from dysphagia. Claim 4: The oral disintegrating tablet according to claim 3, characterized in that the slider is one or more classes of sliders selected from the group consisting of hydrated silicon dioxide, light anhydrous silicic acid, and heavy anhydrous silicic acid. Claim 7: The oral disintegrating tablet according to claim 6, characterized in that the organic excipient is one or more classes of excipients selected from the group consisting of starches and cellulose. Claim 13: The oral disintegrating tablet according to any one of claims 1 to 12 characterized in that it may optionally also comprise one or more classes of additives selected from the group consisting of lubricants, sweeteners, flavoring substances, flavorings, binders and colorants.

ARP090100682A 2008-02-29 2009-02-27 COMPRESSED ORAL DISINTEGRATION AR070530A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008050460 2008-02-29

Publications (1)

Publication Number Publication Date
AR070530A1 true AR070530A1 (en) 2010-04-14

Family

ID=40718911

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100682A AR070530A1 (en) 2008-02-29 2009-02-27 COMPRESSED ORAL DISINTEGRATION

Country Status (7)

Country Link
EP (1) EP2262487A2 (en)
JP (1) JP2011513194A (en)
AR (1) AR070530A1 (en)
CL (1) CL2009000452A1 (en)
PE (1) PE20091560A1 (en)
TW (1) TW200936184A (en)
WO (1) WO2009107864A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158110A2 (en) 2010-04-28 2011-12-22 Nuformix Limited Cilostazol cocrystals and compositions
ES2422657B1 (en) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Cilostazol solid pharmaceutical composition
CN104487094B (en) 2012-07-20 2017-05-17 大塚制药株式会社 Tablet having dry-ink film on surface thereof, and ink for inkjet printer
JP5713421B1 (en) 2013-07-19 2015-05-07 株式会社三和化学研究所 Orally disintegrating tablets
US9974738B2 (en) 2013-09-27 2018-05-22 Daicel Corporation Disintegrating particle composition produced by two-stage wet granulation process, and intraorally disintegrating tablet containing same composition
US10231914B2 (en) * 2015-06-02 2019-03-19 Lynette Batton Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2001076565A1 (en) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
JP4637338B2 (en) * 2000-09-22 2011-02-23 大塚製薬株式会社 Cilostazol dry coated tablets
JP4551627B2 (en) * 2003-02-28 2010-09-29 東和薬品株式会社 Method for producing orally disintegrating tablets
IN234086B (en) * 2003-10-15 2009-05-29 Fuji Chem Ind Co Ltd
JP3841804B2 (en) * 2003-10-15 2006-11-08 富士化学工業株式会社 Composition for intraorally rapidly disintegrating tablets
TWI383809B (en) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd Orally disintegrating powder comprising cilostazol
WO2007029376A1 (en) * 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. Orally rapidly disintegrating tablet

Also Published As

Publication number Publication date
PE20091560A1 (en) 2009-10-30
JP2011513194A (en) 2011-04-28
WO2009107864A3 (en) 2009-12-03
WO2009107864A2 (en) 2009-09-03
EP2262487A2 (en) 2010-12-22
TW200936184A (en) 2009-09-01
CL2009000452A1 (en) 2010-03-26

Similar Documents

Publication Publication Date Title
AR070530A1 (en) COMPRESSED ORAL DISINTEGRATION
ECSP088281A (en) METABOLISM MODULATORS AND TREATMENT OF METABOLIC DISORDERS
UY31816A (en) AGENT FOR THE TREATMENT AND / OR PREVENTION OF AN AUTOIMMUNE DISEASE AND FOR THE FORMATION OF REGULATORY CELLS
AR081776A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING 4-AMINO-5-FLUORO-3- LACTATE MONOHIDRATE [6- (4-METHYL-PIPERAZIN-1-IL) -1H-BENCIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA, PROCESS FOR THE COMPOSITION PRODUCTION
MY152710A (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
MY157661A (en) Bendamustine pharmaceutical compositions
CL2013001586A1 (en) Rapid dispersion microgranular composition comprising at least one sugar alcohol, a saccharide, or a mixture thereof, at least one super disintegrant and at least one multifunctional additive; oral disintegration tablet comprising the microgranular composition and at least one active ingredient; and manufacturing methods.
PE20142440A1 (en) IMMEDIATE RELEASE ORAL PHARMACEUTICAL COMPOSITIONS WITH NON-ENTERIC COATING INCLUDING 5-AZACITIDINE
AR050717A1 (en) PHARMACEUTICAL COMPOSITIONS
CR20110658A (en) ANTAGONISTS OF THE HEDGEHOG CARE OF UNTITUTED FTALAZINA
CL2008003827A1 (en) Composition for orally disintegrating tablets comprising at least one drug (temazepam), 0.5-3% of a binder polymer for odt, a sugar alcohol and / or saccharide, and a disintegrant; method to prepare it; Useful to treat a disease or condition such as a sleep disorder in patients with dysphagia.
UY32820A (en) DP2 RECEPTOR ANTAGONIST DERMATOLOGICAL COMPOSITIONS
UY33392A (en) REPLACED READERS WITH PIPERIDINYL AS MODULATORS OF GPR119
CO6400186A2 (en) ULIPRISTAL ACETATE TABLETS
CL2009000727A1 (en) Substituted n-hydroxy-3-phenylprop-2-enmide and n-hydroxy-3-phenylpropanamide derivative compounds; deacetylase enzyme inhibitors; its pharmaceutical composition; Useful in the treatment of cancer, tumors, psoriasis, Alzheimer's, among others.
MX342181B (en) Formulations comprising polyethylene glycol.
UA94036C2 (en) Bendamustine pharmaceutical compositions for lyophilisation
CL2011000806A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
GT201100336A (en) HETEROCYCLIC SULFONAMIDS, USES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
WO2015038552A3 (en) Aspirin formulation for increased efficacy
CU20140114A7 (en) SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALIL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE
EA201500375A1 (en) COMPOSITION FOR CARE OF THE ORAL CAVITY
CO6300935A2 (en) ORAL AND INJECTABLE FORMULATIONS OF TETRACICLINE COMPOUNDS
BR112014030680A2 (en) effervescent dosage form
DOP2015000089A (en) COMPOSITION OF DIFENIDOL OF PROLONGED RELEASE

Legal Events

Date Code Title Description
FB Suspension of granting procedure